Allegro Ophthalmics is working to establish Integrin Peptide Therapy as a pharmaceutical category for the treatment of vitreo-retinal diseases. Allegro's lead investigational drug, Luminate, is currently in Phase 2 studies and has the potential to reduce the current burden of intravitreal injections and to be a viable option for patients with diabetic macular edema and wet age-related macular degeneration.

Allegro Ophthalmics is working to establish Integrin Peptide Therapy as a pharmaceutical category for the treatment of vitreo-retinal diseases. Allegro's lead investigational drug, Luminate, is currently in Phase 2 studies and has the potential to re...Show all